FIGURE 1.

The figure demonstrates the cumulative incidence of adverse events (fatigue, anorexia and adrenal insufficiency) against months after the start of therapy. Competing risk analysis to modify for competing events like death and progression was done and represented in black dotted‐ fatigue, yellow dotted‐ anorexia and grey dotted‐ adrenal insufficiency (RStudio version 3.5.2). The cumulative incidence of these adverse events was below 10% even with consideration of competing events.